The impact Sequenom will make in the world of prenatal genetic testing alone is mind boggling. They are also developing tests for diseases, including cancer detection, vis-a-vis the same route (blood sampling). When one considers the limited number of shares outstanding (55M) with the vast multi-billion dollar markets they should dominate in the near future makes this look like a dot.com bubble pick without the bubble. It is a game changer!